1
|
Uner OE, Choi D, Hwang TS, Faridi A. Bias Reduction Practices in Underrepresented Groups in Ophthalmology Resident Recruitment. JAMA Ophthalmol 2024; 142:429-435. [PMID: 38546576 PMCID: PMC10979357 DOI: 10.1001/jamaophthalmol.2024.0394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2023] [Accepted: 01/22/2024] [Indexed: 04/01/2024]
Abstract
Importance Best recruitment practices for increasing diversity are well established, but the adoption and impact of these practices in ophthalmology residency recruitment are unknown. Objective To describe the adoption of bias reduction practices in groups underrepresented in ophthalmology (URiO) residency recruitment and determine which practices are effective for increasing URiO residents. Design, Setting, and Participants This cross-sectional survey study used an 18-item questionnaire included in the online survey of the Association of University Professors in Ophthalmology (AUPO) Residency Program Directors. Data collection occurred from July 2022 to December 2022. The data were initially analyzed on January 16, 2023. Participants included residency program directors (PDs) in the AUPO PD listserv database. Main Outcomes and Measures Descriptive analysis of resident selection committee approaches, evaluation of applicant traits, and use of bias reduction tools. Primary outcome was diversity assessed by presence of at least 1 resident in the last 5 classes who identified as URiO, including those underrepresented in medicine (URiM), lesbian, gay, bisexual, transgender, queer, intersex, and asexual plus, or another disadvantaged background (eg, low socioeconomic status). Multivariate analyses of recruitment practices were conducted to determine which practices were associated with increased URiO and URiM. Results Among 106 PDs, 65 completed the survey (61.3%). Thirty-nine PDs used an interview rubric (60.0%), 28 used interview standardization (43.0%), 56 provided at least 1 bias reduction tool to their selection committee (86.2%), and 44 used postinterview metrics to assess diversity, equity, and inclusion efforts (67.7%). Application filters, interview standardization, and postinterview metrics were not associated with increased URiO. Multivariate logistic regression analysis showed larger residency class (odds ratio [OR], 1.34; 95% CI, 1.09-1.65; P = .01) and use of multiple selection committee bias reduction tools (OR, 1.47; 95% CI, 1.13-1.92; P = .01) were positively associated with increased URiO, whereas use of interview rubrics (OR, 0.72; 95% CI, 0.59-0.87; P = .001) and placing higher importance of applicant interest in a program (OR, 0.83; 95% CI, 0.75-0.92; P = .02) were negatively associated. URiM analyses showed similar associations. Conclusions and Relevance Ophthalmology residency interviews are variably standardized. In this study, providing multiple bias reduction tools to selection committees was associated with increased URiO and URiM residents. Prioritizing applicant interest in a program may reduce resident diversity. Interview rubrics, while intended to reduce bias, may inadvertently increase inequity.
Collapse
Affiliation(s)
- Ogul E. Uner
- Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland
| | - Dongseok Choi
- Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland
- Oregon Health & Science University, Portland State University School of Public Health, Portland
| | - Thomas S. Hwang
- Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland
| | - Ambar Faridi
- Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland
- Veteran Affairs Portland Health Care System, Oregon
| |
Collapse
|
2
|
Jansen RW, Roohollahi K, Uner OE, de Jong Y, de Bloeme CM, Göricke S, Sirin S, Maeder P, Galluzzi P, Brisse HJ, Cardoen L, Castelijns JA, van der Valk P, Moll AC, Grossniklaus H, Hubbard GB, de Jong MC, Dorsman J, de Graaf P. Correlation of gene expression with magnetic resonance imaging features of retinoblastoma: a multi-center radiogenomics validation study. Eur Radiol 2024; 34:863-872. [PMID: 37615761 PMCID: PMC10853293 DOI: 10.1007/s00330-023-10054-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2023] [Revised: 04/30/2023] [Accepted: 06/22/2023] [Indexed: 08/25/2023]
Abstract
OBJECTIVES To validate associations between MRI features and gene expression profiles in retinoblastoma, thereby evaluating the repeatability of radiogenomics in retinoblastoma. METHODS In this retrospective multicenter cohort study, retinoblastoma patients with gene expression data and MRI were included. MRI features (scored blinded for clinical data) and matched genome-wide gene expression data were used to perform radiogenomic analysis. Expression data from each center were first separately processed and analyzed. The end product normalized expression values from different sites were subsequently merged by their Z-score to permit cross-sites validation analysis. The MRI features were non-parametrically correlated with expression of photoreceptorness (radiogenomic analysis), a gene expression signature informing on disease progression. Outcomes were compared to outcomes in a previous described cohort. RESULTS Thirty-six retinoblastoma patients were included, 15 were female (42%), and mean age was 24 (SD 18) months. Similar to the prior evaluation, this validation study showed that low photoreceptorness gene expression was associated with advanced stage imaging features. Validated imaging features associated with low photoreceptorness were multifocality, a tumor encompassing the entire retina or entire globe, and a diffuse growth pattern (all p < 0.05). There were a number of radiogenomic associations that were also not validated. CONCLUSIONS A part of the radiogenomic associations could not be validated, underlining the importance of validation studies. Nevertheless, cross-center validation of imaging features associated with photoreceptorness gene expression highlighted the capability radiogenomics to non-invasively inform on molecular subtypes in retinoblastoma. CLINICAL RELEVANCE STATEMENT Radiogenomics may serve as a surrogate for molecular subtyping based on histopathology material in an era of eye-sparing retinoblastoma treatment strategies. KEY POINTS • Since retinoblastoma is increasingly treated using eye-sparing methods, MRI features informing on molecular subtypes that do not rely on histopathology material are important. • A part of the associations between retinoblastoma MRI features and gene expression profiles (radiogenomics) were validated. • Radiogenomics could be a non-invasive technique providing information on the molecular make-up of retinoblastoma.
Collapse
Affiliation(s)
- Robin W Jansen
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Amsterdam, The Netherlands.
| | - Khashayar Roohollahi
- Cancer Center Amsterdam, Amsterdam, The Netherlands
- Department of Oncogenetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Ogul E Uner
- Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, USA
- Emory Eye Center, Ocular Oncology Service, Atlanta, USA
| | - Yvonne de Jong
- Cancer Center Amsterdam, Amsterdam, The Netherlands
- Department of Ophthalmology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Christiaan M de Bloeme
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
- Cancer Center Amsterdam, Amsterdam, The Netherlands
| | - Sophia Göricke
- Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany
| | - Selma Sirin
- Department of Diagnostic Imaging, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Philippe Maeder
- Department of Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | | | | | | | - Jonas A Castelijns
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - Paul van der Valk
- Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Annette C Moll
- Cancer Center Amsterdam, Amsterdam, The Netherlands
- Department of Ophthalmology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | | | | | - Marcus C de Jong
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
- Cancer Center Amsterdam, Amsterdam, The Netherlands
| | - Josephine Dorsman
- Cancer Center Amsterdam, Amsterdam, The Netherlands
- Department of Oncogenetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Pim de Graaf
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
- Cancer Center Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
3
|
Uner OE, Lee D, Horesh R, Jewart B, Seebruck C. Lowering the Incidence of Endophthalmitis Following Intravitreal Anti-VEGF Injection: An Analysis of Aseptic Protocol Adjustment. Ophthalmic Surg Lasers Imaging Retina 2023; 54:520-525. [PMID: 37642415 DOI: 10.3928/23258160-20230808-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/31/2023]
Abstract
BACKGROUND AND OBJECTIVE The impact of anti-sepsis-anesthesia sequence in intravitreal injection (IVI)-associated endophthalmitis is unknown. We compared outcomes of patients who had 10% topical povidone-iodine before or after 2% topical lidocaine gel during IVIs. PATIENTS AND METHODS A retrospective study of IVIs in nine clinical sites was undertaken. Group 1 had lidocaine gel applied first. This protocol was changed on March 1, 2020, with Group 2 having povidone-iodine applied first. Visual and micro-biological outcomes were compared. RESULTS Among 72 cases (0.07%) from 102,908 IVIs, Group 1 had 59 cases from 65,307 IVI (0.09%) and Group 2 had 13 cases from 37,601 IVI (0.03%; P = 0.001). There was no significant difference in the best-corrected visual acuity between groups. Highly virulent bacteria were predominantly isolated in Group 1, but proportions of gram-positive bacterial growth were similar. CONCLUSIONS Application of povidone-iodine before lidocaine gel, compared to after, significantly decreased rate of IVI endophthalmitis, with no significant changes in visual and microbiological outcomes. [Ophthalmic Surg Lasers Imaging Retina 2023;54:520-525.].
Collapse
|
4
|
Oganov AC, Seddon I, Jabbehdari S, Uner OE, Fonoudi H, Yazdanpanah G, Outani O, Arevalo JF. Artificial intelligence in retinal image analysis: Development, advances, and challenges. Surv Ophthalmol 2023; 68:905-919. [PMID: 37116544 DOI: 10.1016/j.survophthal.2023.04.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Revised: 04/20/2023] [Accepted: 04/24/2023] [Indexed: 04/30/2023]
Abstract
Modern advances in diagnostic technologies offer the potential for unprecedented insight into ophthalmic conditions relating to the retina. We discuss the current landscape of artificial intelligence in retina with respect to screening, diagnosis, and monitoring of retinal pathologies such as diabetic retinopathy, diabetic macular edema, central serous chorioretinopathy, and age-related macular degeneration. We review the methods used in these models and evaluate their performance in both research and clinical contexts and discuss potential future directions for investigation, use of multiple imaging modalities in artificial intelligence algorithms, and challenges in the application of artificial intelligence in retinal pathologies.
Collapse
Affiliation(s)
- Anthony C Oganov
- Department of Ophthalmology, Renaissance School of Medicine, Stony Brook, NY, USA
| | - Ian Seddon
- College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA
| | - Sayena Jabbehdari
- Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
| | - Ogul E Uner
- Casey Eye Institute, Department of Ophthalmology, Oregon Health and Science University, Portland, OR, USA
| | - Hossein Fonoudi
- Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Iranshahr University of Medical Sciences, Iranshahr, Sistan and Baluchestan, Iran
| | - Ghasem Yazdanpanah
- Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL, USA
| | - Oumaima Outani
- Faculty of Medicine and Pharmacy of Rabat, Mohammed 5 University, Rabat, Rabat, Morocco
| | - J Fernando Arevalo
- Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
5
|
Uner OE, Hubbard DC, Torres-Quinones C, Pegany R, Huang L, Ponsetto MK, Fletcher M, Sikka MK, Nanji A, Redd TK, Stutzman RD, Chamberlain W, Kim DH. Human MPox (Monkeypox) Virus Membranous Keratoconjunctivitis With Transient Corneal Hypoesthesia and Late Symblepharon Formation: A Novel Case and Clinical Implications. Cornea 2023; 42:751-754. [PMID: 36728311 PMCID: PMC10164038 DOI: 10.1097/ico.0000000000003231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Accepted: 11/30/2022] [Indexed: 02/03/2023]
Abstract
PURPOSE The aim of this study was to describe a case of corneal involvement as an early manifestation of ocular disease in the 2022 human mpox (monkeypox) virus outbreak. METHODS This is a single case report with longitudinal care. RESULTS A 47-year-old immunocompetent man presented with viral conjunctivitis before development of skin lesions or systemic symptoms. Subsequently, he developed membranous keratoconjunctivitis and a corneal epithelial defect. Orthopoxvirus-positive polymerase chain reaction test from his ocular surface was positive. The epithelial defect did not heal with conservative treatment but was successfully treated with amniotic membrane transplantation over 8 days. Reduced corneal sensation was noted after epithelial healing, and polymerase chain reaction from the ocular surface remained positive at 17 days from symptom onset, with slowly recovering conjunctivitis at 21 days. Continued membrane formation required repeated removal but significantly improved with topical corticosteroid treatment after epithelial healing by 29 days of symptom onset. Corneal sensation normalized by 87 days from symptom onset at which time symblepharon were noted but PCR testing from the ocular surface was negative. CONCLUSIONS Early corneal involvement of human monkeypox virus is possible. Transient corneal hypoesthesia may be due to acute inflammation. Chronic inflammatory changes can result in symblepharon. These findings have potential implications in patient care and corneal donation.
Collapse
Affiliation(s)
- Ogul E Uner
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, OR
| | - Donald C Hubbard
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, OR
| | - Carlos Torres-Quinones
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, OR
| | - Roma Pegany
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, OR
| | - Lingling Huang
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, OR
| | - Momoko K Ponsetto
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, OR
| | - Miles Fletcher
- School of Medicine, Oregon Health and Science University, Portland, OR; and
| | - Monica K Sikka
- Department of Medicine, Division of Infectious Diseases, Oregon Health and Science University, Portland, OR
| | - Afshan Nanji
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, OR
| | - Travis K Redd
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, OR
| | - Richard D Stutzman
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, OR
| | - Winston Chamberlain
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, OR
| | - Donna H Kim
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, OR
| |
Collapse
|
6
|
Jansen RW, de Bloeme CM, Cardoen L, Göricke S, van Elst S, Jessen JL, Ramasubramanian A, Skalet AH, Miller AK, Maeder P, Uner OE, Hubbard GB, Grossniklaus H, Boldt HC, Nichols KE, Brennan RC, Sen S, Sirin S, Brisse HJ, Galluzzi P, Dommering CJ, Castelijns JA, van der Valk P, Boellaard R, Dorsman J, Moll AC, de Jong MC, de Graaf P. MRI Features for Identifying MYCN-amplified RB1 Wild-type Retinoblastoma. Radiology 2023; 307:e222264. [PMID: 37191489 PMCID: PMC10315525 DOI: 10.1148/radiol.222264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Revised: 03/06/2023] [Accepted: 03/20/2023] [Indexed: 05/17/2023]
Abstract
Background MYCN-amplified RB1 wild-type (MYCNARB1+/+) retinoblastoma is a rare but clinically important subtype of retinoblastoma due to its aggressive character and relative resistance to typical therapeutic approaches. Because biopsy is not indicated in retinoblastoma, specific MRI features might be valuable to identify children with this genetic subtype. Purpose To define the MRI phenotype of MYCNARB1+/+ retinoblastoma and evaluate the ability of qualitative MRI features to help identify this specific genetic subtype. Materials and Methods In this retrospective, multicenter, case-control study, MRI scans in children with MYCNARB1+/+ retinoblastoma and age-matched children with RB1-/- subtype retinoblastoma were included (case-control ratio, 1:4; scans acquired from June 2001 to February 2021; scans collected from May 2018 to October 2021). Patients with histopathologically confirmed unilateral retinoblastoma, genetic testing (RB1/MYCN status), and MRI scans were included. Associations between radiologist-scored imaging features and diagnosis were assessed with the Fisher exact test or Fisher-Freeman-Halton test, and Bonferroni-corrected P values were calculated. Results A total of 110 patients from 10 retinoblastoma referral centers were included: 22 children with MYCNARB1+/+ retinoblastoma and 88 control children with RB1-/- retinoblastoma. Children in the MYCNARB1+/+ group had a median age of 7.0 months (IQR, 5.0-9.0 months) (13 boys), while children in the RB1-/- group had a median age of 9.0 months (IQR, 4.6-13.4 months) (46 boys). MYCNARB1+/+ retinoblastomas were typically peripherally located (in 10 of 17 children; specificity, 97%; P < .001) and exhibited plaque or pleomorphic shape (in 20 of 22 children; specificity, 51%; P = .011) with irregular margins (in 16 of 22 children; specificity, 70%; P = .008) and extensive retina folding with vitreous enclosure (specificity, 94%; P < .001). MYCNARB1+/+ retinoblastomas showed peritumoral hemorrhage (in 17 of 21 children; specificity, 88%; P < .001), subretinal hemorrhage with a fluid-fluid level (in eight of 22 children; specificity, 95%; P = .005), and strong anterior chamber enhancement (in 13 of 21 children; specificity, 80%; P = .008). Conclusion MYCNARB1+/+ retinoblastomas show distinct MRI features that could enable early identification of these tumors. This may improve patient selection for tailored treatment in the future. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Rollins in this issue.
Collapse
Affiliation(s)
- Robin W. Jansen
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Christiaan M. de Bloeme
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Liesbeth Cardoen
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Sophia Göricke
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Sabien van Elst
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Jaime Lyn Jessen
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Aparna Ramasubramanian
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Alison H. Skalet
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Audra K. Miller
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Philippe Maeder
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Ogul E. Uner
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - G. Baker Hubbard
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Hans Grossniklaus
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - H. Culver Boldt
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Kim E. Nichols
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Rachel C. Brennan
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Saugata Sen
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Selma Sirin
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Hervé J. Brisse
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Paolo Galluzzi
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Charlotte J. Dommering
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Jonas A. Castelijns
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Paul van der Valk
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Ronald Boellaard
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Josephine Dorsman
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Annette C. Moll
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Marcus C. de Jong
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Pim de Graaf
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| |
Collapse
|
7
|
Uner OE, Aronow ME, Mruthyunjaya P, Materin MA, Stacey AW, Wilson M, Afshar A, Skalet AH. Uveal Melanoma and the IRIS® Registry (Intelligent Research in Sight): A Pilot Analysis and Future Directions. Ophthalmol Retina 2023; 7:284-286. [PMID: 36522810 DOI: 10.1016/j.oret.2022.10.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Revised: 10/15/2022] [Accepted: 10/25/2022] [Indexed: 11/16/2022]
Affiliation(s)
- Ogul E Uner
- Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland, Oregon
| | - Mary E Aronow
- Retina Service, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts
| | - Prithvi Mruthyunjaya
- Department of Ophthalmology, Byers Eye Institute, Stanford School of Medicine, Palo Alto, California
| | - Miguel A Materin
- Department of Ophthalmology, Duke University Eye Center, Durham, North Carolina; Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina
| | - Andrew W Stacey
- Department of Ophthalmology, University of Washington, Seattle, Washington
| | - Matthew Wilson
- Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, Tennessee; Ocular Oncology Division, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Armin Afshar
- Ocular Oncology Service, Department of Ophthalmology, Wayne & Gladys Valley Center for Vision, University of California, San Francisco, San Francisco, California
| | - Alison H Skalet
- Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland, Oregon; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon; Department of Radiation Medicine, Oregon Health & Science University, Portland, Oregon; Department of Dermatology, Oregon Health & Science University, Portland, Oregon.
| |
Collapse
|
8
|
Uner OE, Lin P. Bilateral Macular Toxoplasmosis. Ophthalmol Retina 2022; 6:1018. [PMID: 36100532 DOI: 10.1016/j.oret.2022.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Revised: 08/10/2022] [Accepted: 08/11/2022] [Indexed: 10/14/2022]
Affiliation(s)
- Ogul E Uner
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon
| | - Phoebe Lin
- Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon
| |
Collapse
|
9
|
Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Abdulrahaman AA, Abouelnaga S, Ademola-Popoola DS, Adio A, Afifi MA, Afshar AR, Aggarwal P, Aghaji AE, Ahmad A, Akib MNR, Akinsete A, Al Harby L, Al Mesfer S, Al Ani MH, Alarcón Portabella S, Al-Badri SAF, Alcasabas APA, Al-Dahmash SA, Alejos A, Alemany-Rubio E, Alfa Bio AI, Alfonso Carreras Y, Al-Haddad CE, Al-Hussaini HHY, Ali AM, Alia DB, Al-Jadiry MF, Al-Jumaily U, Alkatan HM, All-Eriksson C, Al-Mafrachi AARM, Almeida AA, Alsawidi KM, Al-Shaheen AASM, Al-Shammary EH, Amankwaa-Frempong D, Amiruddin PO, Armytasari I, Astbury NJ, Atalay HT, Ataseven E, Atchaneeyasakul LO, Atsiaya R, Autrata R, Balaguer J, Balayeva R, Barranco H, Bartoszek P, Bartuma K, Bascaran C, Bechrakis NE, Beck Popovic M, Begimkulova AS, Benmiloud S, Berete RC, Berry JL, Bhaduri A, Bhat S, Bhattacharyya A, Biewald EM, Binkley E, Blum S, Bobrova N, Boldt H, Bonanomi MTBC, Bouda GC, Bouguila H, Brennan RC, Brichard BG, Buaboonnam J, Budiongo A, Burton MJ, Calderón-Sotelo P, Calle Jara DA, Camuglia JE, Cano MR, Capra M, Caspi S, Cassoux N, Castela G, Castillo L, Català-Mora J, Cavieres I, Chandramohan A, Chantada GL, Chaudhry S, Chawla B, Chen W, Chiwanga FS, Chuluunbat T, Cieslik K, Clark A, Cockcroft RL, Comsa C, Correa Llano MG, Corson TW, Couitchere L, Cowan-Lyn KE, Csóka M, Dangboon W, Das A, Das P, Das S, Davanzo JM, Davidson A, De Francesco S, De Potter P, Quintero D K, Demirci H, Desjardins L, Díaz Coronado RY, Dimaras H, Dodgshun AJ, Donato Macedo CR, Dragomir MD, Du Y, Du Bruyn M, Du Plessis J, Dudeja G, Eerme K, Eka Sutyawan IW, El Kettani A, Elbahi AM, Elder JE, Elhaddad AM, Elhassan MMA, Elzembely MM, Ericksen C, Essuman VA, Evina TGA, Ezegwui IR, Fadoo Z, Fandiño AC, Faranoush M, Fasina O, Fernández DDPG, Fernández-Teijeiro A, Foster A, Frenkel S, Fu LD, Fuentes-Alabi SL, Garcia JL, García Aldana D, Garcia Pacheco HN, Geel JA, Ghassemi F, Girón AV, Goenz MA, Gold AS, Goldberg H, Gole GA, Gomel N, Gonzalez E, Gonzalez Perez G, González-Rodríguez L, Gorfine M, Graells J, Gregersen PA, Grigorovski NDAK, Guedenon KM, Gunasekera DS, Gündüz AK, Gupta H, Gupta S, Gupta V, Hadjistilianou T, Hamel P, Hamid SA, Hamzah N, Hansen ED, Harbour JW, Hartnett ME, Hasanreisoglu M, Muhammad H, Hassan S, Hassan S, Hautz W, Haydar H, Hederova S, Hessissen L, Hongeng S, Hordofa DF, Hubbard GB, Hummelen M, Husakova K, Hussein Al-Janabi AN, Ibanga A, Ida R, Ilic VR, Islamov Z, Jairaj V, Janjua T, Jeeva I, Ji X, Jo DH, Jones MM, Kabesha Amani TB, Kabore RL, Kaliki S, Kalinaki A, Kamsang P, Kantar M, Kapelushnik N, Kardava T, Kebudi R, Keomisy J, Kepak T, Ketteler P, Khan ZJ, Khaqan HA, Khetan V, Khodabande A, Khotenashvili Z, Kim JW, Kim JH, Kiratli H, Kivela TT, Klett A, Koç I, Kosh Komba Palet JE, Krivaitiene D, Kruger M, Kulvichit K, Kuntorini MW, Kyara A, Lam GC, Larson SA, Latinović S, Laurenti KD, Lavy Y, Lavric Groznik A, Leverant AA, Li C, Li K, Limbu B, Liu CH, Quah B, López JP, Lukamba RM, Luna-Fineman S, Lutfi D, Lysytsia L, Madgar S, Magrath GN, Mahajan A, Maitra P, Maka E, Makimbetov EK, Maktabi A, Maldonado C, Mallipatna A, Manudhane R, Manzhuova L, Martín-Begue N, Masud S, Matende IO, Mattosinho CCDS, Matua M, Mayet I, Mbumba FB, McKenzie JD, Mehrvar A, Mengesha AA, Menon V, Mercado GJV, Mets MB, Midena E, Miller A, Mishra DKC, Mndeme FG, Mohamedani AA, Mohammad MT, Moll AC, Montero MM, Moreira C, Mruthyunjaya P, Msina MS, Msukwa G, Mudaliar SS, Muma KIM, Munier FL, Murray TG, Musa KO, Mushtaq A, Musika AA, Mustak H, Mustapha T, Muyen OM, Myezo KH, Naidu G, Naidu N, Nair AG, Natarajan S, Naumenko L, Ndoye Roth PA, Nency YM, Neroev V, Ng Y, Nikitovic M, Nkanga ED, Nkumbe HE, Numbi MN, Nummi K, Nuruddin M, Nyaywa M, Nyirenda C, Obono-Obiang G, Oliver SCN, Oporto J, Ortega-Hernández M, Oscar AH, Ossandon D, Pagarra H, Paintsil V, Paiva L, Palanivelu MS, Papyan R, Parrozzani R, Pascual Morales CR, Paton KE, Pe'er J, Peralta Calvo J, Perić S, Pham CTM, Philbert R, Plager DA, Pochop P, Polania RA, Polyakov V, Ponce J, Qadir AO, Qayyum S, Qian J, Refaeli D, Rahman A, Rajkarnikar P, Ramanjulu R, Ramasubramanian A, Ramirez-Ortiz MA, Randhawa JK, Randrianarisoa HL, Raobela L, Rashid R, Reddy M, Renner LA, Reynders D, Ribadu D, Ritter-Sovinz P, Rogowska A, Rojanaporn D, Romero L, Roy SR, Saab RH, Saakyan S, Sabhan AH, Sagoo MS, Said AMA, Saiju R, Salas B, San Román Pacheco S, Sánchez GL, Sanchez Orozco AJ, Sayalith P, Scanlan TA, Schlüter S, Schwab C, Sedaghat A, Seth R, Sgroi M, Shah AS, Shakoor SA, Sharma MK, Sherief ST, Shields CL, Sia D, Siddiqui SN, Sidi cheikh S, Silva S, Singh AD, Singh U, Singha P, Sitorus RS, Skalet AH, Soebagjo HD, Sorochynska T, Ssali G, Stacey AW, Staffieri SE, Stahl ED, Steinberg DM, Stones DK, Strahlendorf C, Suarez MEC, Sultana S, Sun X, Superstein R, Supriyadi E, Surukrattanaskul S, Suzuki S, Svojgr K, Sylla F, Tamamyan G, Tan D, Tandili A, Tang J, Tarrillo Leiva FF, Tashvighi M, Tateshi B, Teh KH, Tehuteru ES, Teixeira LF, Tekavcic Pompe M, Thawaba ADM, Theophile T, Toledano H, Trang DL, Traoré F, Tripathy D, Tuncer S, Tyau-Tyau H, Umar AB, Unal E, Uner OE, Urbak SF, Ushakova TL, Usmanov RH, Valeina S, Valente P, van Hoefen Wijsard M, Vasquez Anchaya JK, Vaughan LO, Veleva-Krasteva NV, Verma N, Victor AA, Viksnins M, Villacís Chafla EG, Villegas VM, Vishnevskia-Dai V, Waddell K, Wali AH, Wang YZ, Wangtiraumnuay N, Wetter J, Widiarti W, Wilson MW, Wime ADC, Wiwatwongwana A, Wiwatwongwana D, Wolley Dod C, Wong ES, Wongwai P, Wu SQ, Xiang D, Xiao Y, Xu B, Xue K, Yaghy A, Yam JC, Yang H, Yanga JM, Yaqub MA, Yarovaya VA, Yarovoy AA, Ye H, Yee RI, Yousef YA, Yuliawati P, Zapata López AM, Zein E, Zhang Y, Zhilyaeva K, Zia N, Ziko OAO, Zondervan M, Bowman R. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet Global Health 2022; 10:e1128-e1140. [PMID: 35839812 PMCID: PMC9397647 DOI: 10.1016/s2214-109x(22)00250-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Revised: 05/06/2022] [Accepted: 05/23/2022] [Indexed: 02/01/2023] Open
Abstract
Background Retinoblastoma is the most common intraocular cancer worldwide. There is some evidence to suggest that major differences exist in treatment outcomes for children with retinoblastoma from different regions, but these differences have not been assessed on a global scale. We aimed to report 3-year outcomes for children with retinoblastoma globally and to investigate factors associated with survival. Methods We did a prospective cluster-based analysis of treatment-naive patients with retinoblastoma who were diagnosed between Jan 1, 2017, and Dec 31, 2017, then treated and followed up for 3 years. Patients were recruited from 260 specialised treatment centres worldwide. Data were obtained from participating centres on primary and additional treatments, duration of follow-up, metastasis, eye globe salvage, and survival outcome. We analysed time to death and time to enucleation with Cox regression models. Findings The cohort included 4064 children from 149 countries. The median age at diagnosis was 23·2 months (IQR 11·0–36·5). Extraocular tumour spread (cT4 of the cTNMH classification) at diagnosis was reported in five (0·8%) of 636 children from high-income countries, 55 (5·4%) of 1027 children from upper-middle-income countries, 342 (19·7%) of 1738 children from lower-middle-income countries, and 196 (42·9%) of 457 children from low-income countries. Enucleation surgery was available for all children and intravenous chemotherapy was available for 4014 (98·8%) of 4064 children. The 3-year survival rate was 99·5% (95% CI 98·8–100·0) for children from high-income countries, 91·2% (89·5–93·0) for children from upper-middle-income countries, 80·3% (78·3–82·3) for children from lower-middle-income countries, and 57·3% (52·1-63·0) for children from low-income countries. On analysis, independent factors for worse survival were residence in low-income countries compared to high-income countries (hazard ratio 16·67; 95% CI 4·76–50·00), cT4 advanced tumour compared to cT1 (8·98; 4·44–18·18), and older age at diagnosis in children up to 3 years (1·38 per year; 1·23–1·56). For children aged 3–7 years, the mortality risk decreased slightly (p=0·0104 for the change in slope). Interpretation This study, estimated to include approximately half of all new retinoblastoma cases worldwide in 2017, shows profound inequity in survival of children depending on the national income level of their country of residence. In high-income countries, death from retinoblastoma is rare, whereas in low-income countries estimated 3-year survival is just over 50%. Although essential treatments are available in nearly all countries, early diagnosis and treatment in low-income countries are key to improving survival outcomes. Funding Queen Elizabeth Diamond Jubilee Trust.
Collapse
|
10
|
Uner OE, Nanji AA, Skalet AH. Unilateral Intraocular Lens Implant Subluxation in an Adult. JAMA Ophthalmol 2022; 140:648-649. [PMID: 35420646 DOI: 10.1001/jamaophthalmol.2022.0013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Ogul E Uner
- Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland
| | - Afshan A Nanji
- Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland.,Knight Cancer Institute, Oregon Health & Science University, Portland
| | - Alison H Skalet
- Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland.,Knight Cancer Institute, Oregon Health & Science University, Portland.,Department of Radiation Medicine, Oregon Health & Science University, Portland.,Department of Dermatology, Oregon Health & Science University, Portland
| |
Collapse
|
11
|
Uner OE, Gandrakota N, Azarcon CP, Grossniklaus HE. Animal models of uveal melanoma. Ann Eye Sci 2022; 7. [PMID: 35350473 PMCID: PMC8959478 DOI: 10.21037/aes-21-30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Ogul E. Uner
- Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, USA
| | - Nikhila Gandrakota
- Department of Family Medicine, Emory University School of Medicine, Atlanta, GA, USA
- Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - Corrina P. Azarcon
- Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, USA
| | - Hans E. Grossniklaus
- Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, USA
- Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA
| |
Collapse
|
12
|
Martini DJ, Evans ST, Liu Y, Shabto JM, Uner OE, Olsen TA, Brown JT, Russler GA, Yantorni L, Caulfield S, Goldman JM, Nazha B, Harris WB, Master VA, Kucuk O, Carthon BC, Bilen MA. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. Clin Genitourin Cancer 2022; 20:53-59. [PMID: 34922840 PMCID: PMC8816843 DOI: 10.1016/j.clgc.2021.11.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 11/01/2021] [Accepted: 11/07/2021] [Indexed: 02/03/2023]
Abstract
BACKGROUND Full dose cabozantinib for metastatic renal cell carcinoma (mRCC) is 60 mg, but adverse events (AEs) may require dose reductions. Limited data exist comparing efficacy among cabozantinib doses. We compared AEs and clinical outcomes in mRCC patients treated with full vs. reduced starting cabozantinib dose. METHODS We performed a retrospective analysis of 87 mRCC patients treated with cabozantinib at Winship Cancer Institute from 2016 to 2019. Overall survival (OS), progression-free survival (PFS), and objective response (OR) rate measured clinical outcomes. AEs were collected from clinic notes and the most common were hypertension, mucositis/hand-foot skin reaction (HFSR), or gastrointestinal toxicity. Univariate analysis (UVA) between starting doses and AEs with clinical outcomes was performed using logistic regression model. Multivariable analysis was also performed using Cox proportional hazard model. RESULTS Most patients were men (71%) with clear-cell RCC (72%). The majority were IMDC intermediate (58%) or poor (35%) risk. One third received first-line cabozantinib and 64% had ≥3 baseline metastatic sites. Most patients (68%) required dose reduction from 60 mg or started at reduced dose without escalation. Reduced dose patients were more likely to have ≥3 distant metastatic sites (70% vs. 58%) and ≥2 prior lines of systemic therapy (50% vs. 40%) compared to full dose patients. UVA revealed a trend towards shorter OS (HR: 1.78, P = .095), PFS (HR: 1.50, P = .107), and lower chance of OR (HR:0.42, P = .149) among reduced dose patients. This trend did not hold in Multivariable analysis (OS HR: 1.20, P = .636; PFS HR: 1.23, P = .4662). Mucositis/HFSR and hypertension were significantly associated with improved outcomes in UVA. CONCLUSIONS Although we found a trend favoring full dose cabozantinib, this is likely due to worse baseline disease characteristics among patients starting on a reduced dose. Hypertension and mucositis/HFSR may be associated with improved outcomes. Larger studies are warranted to validate these findings.
Collapse
Affiliation(s)
- Dylan J. Martini
- Massachusetts General Hospital, Department of Medicine, Boston, MA, USA,Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - Sean T. Evans
- Winship Cancer Institute of Emory University, Atlanta, GA, USA,Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - Yuan Liu
- Departments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA
| | - Julie M. Shabto
- Winship Cancer Institute of Emory University, Atlanta, GA, USA,Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - Ogul E. Uner
- Winship Cancer Institute of Emory University, Atlanta, GA, USA,Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - T. Anders Olsen
- Winship Cancer Institute of Emory University, Atlanta, GA, USA,Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - Jacqueline T. Brown
- Winship Cancer Institute of Emory University, Atlanta, GA, USA,Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | | | - Lauren Yantorni
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - Sarah Caulfield
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA,Department of Pharmaceutical Services, Emory University School of Medicine, Atlanta, GA, USA
| | - Jamie M. Goldman
- Winship Cancer Institute of Emory University, Atlanta, GA, USA,Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - Bassel Nazha
- Winship Cancer Institute of Emory University, Atlanta, GA, USA,Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - Wayne B. Harris
- Winship Cancer Institute of Emory University, Atlanta, GA, USA,Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - Viraj A. Master
- Department of Urology, Emory University School of Medicine, Atlanta, GA, USA
| | - Omer Kucuk
- Winship Cancer Institute of Emory University, Atlanta, GA, USA,Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - Bradley C. Carthon
- Winship Cancer Institute of Emory University, Atlanta, GA, USA,Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - Mehmet Asim Bilen
- Winship Cancer Institute of Emory University, Atlanta, GA, USA,Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA,Corresponding Author: Dr. Mehmet A. Bilen, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Rd, Atlanta, GA, USA. Phone: 404-778-3693,
| |
Collapse
|
13
|
Abstract
PURPOSE To investigate patient-reported visual function among individuals taking pentosan polysulfate (PPS) for interstitial cystitis. METHODS A 27-item online survey was distributed to an international mailing list of individuals with interstitial cystitis in November 2018. Demographic characteristics, PPS exposure history, subjective visual function, and previous macular diagnoses were queried. The impact of PPS use, grouped by tertile of cumulative exposure, on visual function and macular diagnoses was assessed with multivariate logistic regression. RESULTS The survey was completed by 912 respondents. Eight hundred and sixty-one (96.4%) were women, and the median age was 55 [interquartile range (IQR), 45-64 years]. Among PPS users, the median exposure was 547.5 g (IQR, 219-1,314 g). Respondents in the highest PPS exposure tertile were more likely to report difficulty with reading small print [adjusted odds ratio 2.29, 95% confidence interval (CI) 1.15-4.57] and to have a diagnosis of macular degeneration and/or pigmentary maculopathy (adjusted odds ratio 2.41, 95% CI 1.44-4.03) than unexposed respondents. CONCLUSION In this large sample of individuals with interstitial cystitis, those in the highest PPS exposure category were more likely to have difficulties reading small print and to report a previous diagnosis of macular disease. Further study of objective measures of visual function in PPS users is warranted.
Collapse
Affiliation(s)
- Ogul E Uner
- Emory University School of Medicine, Atlanta, Georgia
| | - Megha K Shah
- Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, Georgia ; and
| | - Nieraj Jain
- Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia
| |
Collapse
|
14
|
Uner OE, See TRO, Szalai E, Grossniklaus HE, Stålhammar G. Estimation of the timing of BAP1 mutation in uveal melanoma progression. Sci Rep 2021; 11:8923. [PMID: 33903674 PMCID: PMC8076235 DOI: 10.1038/s41598-021-88390-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Accepted: 04/12/2021] [Indexed: 01/17/2023] Open
Abstract
Uveal melanoma is the most common primary intraocular malignancy. A vast majority of metastasizing tumors have mutations in the BAP1 gene. Here, we investigate the spatiotemporal timing of these mutations. The size of 177 uveal melanomas and 8.3 million individual tumor cells was measured. BAP1 sequencing results and BAP1 IHC were available and for 76 (43%) and 101 (57%) of these, respectively. Tumors with a BAP1 mutation had significantly larger volume (2109 vs. 1552 mm3, p = 0.025). Similarly, tumor cells with loss of BAP1 protein expression had significantly larger volume (2657 vs. 1593 μm3, p = 0.027). Using observations of the time elapsed between mitoses, the BAP1 mutation was calculated to occur when the primary tumor had a size of a few malignant cells to 6 mm3, 0.5 to 4.6 years after tumor initiation and at least 9 years before diagnosis. We conclude that BAP1 mutations occur early in the growth of uveal melanoma, well before the average tumor is diagnosed. Its timing coincides with the seeding of micrometastases.
Collapse
Affiliation(s)
- Ogul E Uner
- Emory University School of Medicine, Atlanta, Georgia, USA.,Departments of Ophthalmology and Pathology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Thonnie Rose O See
- Departments of Ophthalmology and Pathology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Eszter Szalai
- Department of Ophthalmology, University of Pécs Medical School, Pécs, Hungary
| | - Hans E Grossniklaus
- Departments of Ophthalmology and Pathology, Emory University School of Medicine, Atlanta, Georgia, USA.
| | - Gustav Stålhammar
- St. Erik Eye Hospital, Stockholm, Sweden. .,Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
15
|
Yeung A, Uner OE, Wells JR, Grossniklaus HE. Clinical and Histopathological Features of Corneal Primary Acquired Melanosis and Melanoma. Ocul Oncol Pathol 2021; 7:103-107. [PMID: 33981694 DOI: 10.1159/000511596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Accepted: 09/14/2020] [Indexed: 11/19/2022] Open
Abstract
Aim The aim of this study is to describe the clinical and pathologic features of corneal primary acquired melanosis (PAM) and melanoma. Methods We describe 3 cases in total: two cases of corneal melanomas and 1 case of corneal PAM. The eyes were processed routinely for histopathological examination. Clinical histories, treatments, and outcomes were reviewed. Results Corneal melanomas arose from recurrence of conjunctival melanoma or conjunctival PAM at the limbus. One patient had a recurrence after excision of a limbal melanoma, another had a de novo corneal melanoma, and the last patient had corneal PAM in the setting of conjunctival PAM with atypia. All lesions were excised with adjuvant alcohol debridement and cryotherapy with no recurrence ranging from 1 week to 8 years. Conclusions Corneal melanomas arise at the limbus from corneal PAM or conjunctival atypia. They can appear after excisional removal of a conjunctival melanoma. Surgical excision with alcohol debridement and adjuvant cryotherapy is successful.
Collapse
Affiliation(s)
- Aaron Yeung
- Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Ogul E Uner
- School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Jill R Wells
- Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Hans E Grossniklaus
- Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA.,Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA
| |
Collapse
|
16
|
Uner OE, Stelton CR, Hubbard GB, Rao P. Visual and Anatomic Outcomes of Premacular Hemorrhage in Non-Accidental Trauma Infants Managed With Observation or Vitrectomy. Ophthalmic Surg Lasers Imaging Retina 2020; 51:715-722. [PMID: 33339053 DOI: 10.3928/23258160-20201202-06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Accepted: 10/07/2020] [Indexed: 11/20/2022]
Abstract
BACKGROUND AND OBJECTIVE The management of premacular hemorrhage secondary to non-accidental trauma (NAT) is unclear. The authors describe the outcomes of NAT infants referred for surgical evaluation of premacular hemorrhage. PATIENTS AND METHODS Retrospective institutional review board-approved case series between 2000 and 2019 of vision-threatening premacular hemorrhage (sub-hyaloid or sub-internal limiting membrane hemorrhage without vitreous hemorrhage) in NAT infants. Time to hemorrhage resolution, vision, and comorbidities were collected. RESULTS Thirty-six patients (62 eyes) with mean age of 5.4 months (range: 2-10 months) were included. Nine eyes (14.5%) underwent vitrectomy. Median time to hemorrhage resolution by observation was 75 days (interquartile range [IQR]: 60-120 days), and time to vitrectomy was 54.5 days (IQR: 47.8-58.5 days). Eight eyes (12.9%) had amblyopia, which was not significantly different between groups. Despite hemorrhage clearance, a higher proportion of eyes in the vitrectomy group had pigmentary changes (P = .04) and strabismus (P = .002) at follow-up. CONCLUSIONS Most cases of NAT-related premacular hemorrhage resolve within 3 months without surgical intervention. Comorbidities may limit visual prognosis. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:715-722.].
Collapse
|
17
|
Abstract
Background The novel coronavirus disease (COVID-19) has created obstacles for medical student education, as clinical rotations were temporarily halted. Recent literature shows online electives may provide an alternative learning platform. We developed a tele-ophthalmology student elective for rising third-year (MS3) and fourth-year (MS4) medical students to continue teaching and exposure to the field. Methods A 4-week remote elective was approved by Emory University School of Medicine and offered between April 18, 2020 to May 15, 2020 for rising MS3 and MS4 students. The curriculum consisted of online self-study materials, student presentations, chart review assignments, case-based discussions with faculty, and telehealth experiences. All students were surveyed and tested with questions from USMLE World (UWorld) test bank at the end of the course. Results A total of 18 students enrolled, with 66.7% MS3 and 33.3% MS4 participance. The mean rating of fulfillment of course learning objectives was 8.1/10 (range, 6.7-8.8), with mean ratings of 8.2 for MS3s and 7.7 for MS4s. There was a significant increase in self-reported knowledge in ophthalmology, with an increase from 4.6 to 8.1 for MS3s (p=0.002) and 6.7 to 8.0 for MS4s (p=0.04). Students also reported higher interest in the field, with an increase from 4.9 to 7.8 for MS3s (p=0.01) and 7.5 to 8.7 for MS4s (p=0.1). The students performed significantly higher on the post-course test (94.8%) than UWorld question bank users (74.1%) (p<0.001). Conclusion Our novel ophthalmology elective significantly enhanced self-reported medical student knowledge and interest in the field during a crisis that required transition to remote learning. Further study of student telehealth experience and objective assessment is needed to improve online learning in ophthalmology.
Collapse
Affiliation(s)
| | - Ogul E Uner
- Emory University School of Medicine, Atlanta, Georgia
| | - Yousuf M Khalifa
- Emory University School of Medicine, Atlanta, Georgia.,Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia
| | - Emily B Graubart
- Emory University School of Medicine, Atlanta, Georgia.,Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia
| |
Collapse
|
18
|
Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, Ademola-Popoola DS, Adio A, Afshar AR, Aggarwal P, Aghaji AE, Ahmad A, Akib MNR, Al Harby L, Al Ani MH, Alakbarova A, Portabella SA, Al-Badri SAF, Alcasabas APA, Al-Dahmash SA, Alejos A, Alemany-Rubio E, Alfa Bio AI, Alfonso Carreras Y, Al-Haddad C, Al-Hussaini HHY, Ali AM, Alia DB, Al-Jadiry MF, Al-Jumaily U, Alkatan HM, All-Eriksson C, Al-Mafrachi AARM, Almeida AA, Alsawidi KM, Al-Shaheen AASM, Al-Shammary EH, Amiruddin PO, Antonino R, Astbury NJ, Atalay HT, Atchaneeyasakul LO, Atsiaya R, Attaseth T, Aung TH, Ayala S, Baizakova B, Balaguer J, Balayeva R, Balwierz W, Barranco H, Bascaran C, Beck Popovic M, Benavides R, Benmiloud S, Bennani Guebessi N, Berete RC, Berry JL, Bhaduri A, Bhat S, Biddulph SJ, Biewald EM, Bobrova N, Boehme M, Boldt HC, Bonanomi MTBC, Bornfeld N, Bouda GC, Bouguila H, Boumedane A, Brennan RC, Brichard BG, Buaboonnam J, Calderón-Sotelo P, Calle Jara DA, Camuglia JE, Cano MR, Capra M, Cassoux N, Castela G, Castillo L, Català-Mora J, Chantada GL, Chaudhry S, Chaugule SS, Chauhan A, Chawla B, Chernodrinska VS, Chiwanga FS, Chuluunbat T, Cieslik K, Cockcroft RL, Comsa C, Correa ZM, Correa Llano MG, Corson TW, Cowan-Lyn KE, Csóka M, Cui X, Da Gama IV, Dangboon W, Das A, Das S, Davanzo JM, Davidson A, De Potter P, Delgado KQ, Demirci H, Desjardins L, Diaz Coronado RY, Dimaras H, Dodgshun AJ, Donaldson C, Donato Macedo CR, Dragomir MD, Du Y, Du Bruyn M, Edison KS, Eka Sutyawan IW, El Kettani A, Elbahi AM, Elder JE, Elgalaly D, Elhaddad AM, Elhassan MMA, Elzembely MM, Essuman VA, Evina TGA, Fadoo Z, Fandiño AC, Faranoush M, Fasina O, Fernández DDPG, Fernández-Teijeiro A, Foster A, Frenkel S, Fu LD, Fuentes-Alabi SL, Gallie BL, Gandiwa M, Garcia JL, García Aldana D, Gassant PY, Geel JA, Ghassemi F, Girón AV, Gizachew Z, Goenz MA, Gold AS, Goldberg-Lavid M, Gole GA, Gomel N, Gonzalez E, Gonzalez Perez G, González-Rodríguez L, Garcia Pacheco HN, Graells J, Green L, Gregersen PA, Grigorovski NDAK, Guedenon KM, Gunasekera DS, Gündüz AK, Gupta H, Gupta S, Hadjistilianou T, Hamel P, Hamid SA, Hamzah N, Hansen ED, Harbour JW, Hartnett ME, Hasanreisoglu M, Hassan S, Hassan S, Hederova S, Hernandez J, Hernandez LMC, Hessissen L, Hordofa DF, Huang LC, Hubbard GB, Hummlen M, Husakova K, Hussein Al-Janabi AN, Ida R, Ilic VR, Jairaj V, Jeeva I, Jenkinson H, Ji X, Jo DH, Johnson KP, Johnson WJ, Jones MM, Kabesha TBA, Kabore RL, Kaliki S, Kalinaki A, Kantar M, Kao LY, Kardava T, Kebudi R, Kepak T, Keren-Froim N, Khan ZJ, Khaqan HA, Khauv P, Kheir WJ, Khetan V, Khodabande A, Khotenashvili Z, Kim JW, Kim JH, Kiratli H, Kivelä TT, Klett A, Komba Palet JEK, Krivaitiene D, Kruger M, Kulvichit K, Kuntorini MW, Kyara A, Lachmann ES, Lam CPS, Lam GC, Larson SA, Latinovic S, Laurenti KD, Le BHA, Lecuona K, Leverant AA, Li C, Limbu B, Long QB, López JP, Lukamba RM, Lumbroso L, Luna-Fineman S, Lutfi D, Lysytsia L, Magrath GN, Mahajan A, Majeed AR, Maka E, Makan M, Makimbetov EK, Manda C, Martín Begue N, Mason L, Mason JO, Matende IO, Materin M, Mattosinho CCDS, Matua M, Mayet I, Mbumba FB, McKenzie JD, Medina-Sanson A, Mehrvar A, Mengesha AA, Menon V, Mercado GJVD, Mets MB, Midena E, Mishra DKC, Mndeme FG, Mohamedani AA, Mohammad MT, Moll AC, Montero MM, Morales RA, Moreira C, Mruthyunjaya P, Msina MS, Msukwa G, Mudaliar SS, Muma KI, Munier FL, Murgoi G, Murray TG, Musa KO, Mushtaq A, Mustak H, Muyen OM, Naidu G, Nair AG, Naumenko L, Ndoye Roth PA, Nency YM, Neroev V, Ngo H, Nieves RM, Nikitovic M, Nkanga ED, Nkumbe H, Nuruddin M, Nyaywa M, Obono-Obiang G, Oguego NC, Olechowski A, Oliver SCN, Osei-Bonsu P, Ossandon D, Paez-Escamilla MA, Pagarra H, Painter SL, Paintsil V, Paiva L, Pal BP, Palanivelu MS, Papyan R, Parrozzani R, Parulekar M, Pascual Morales CR, Paton KE, Pawinska-Wasikowska K, Pe'er J, Peña A, Peric S, Pham CTM, Philbert R, Plager DA, Pochop P, Polania RA, Polyakov VG, Pompe MT, Pons JJ, Prat D, Prom V, Purwanto I, Qadir AO, Qayyum S, Qian J, Rahman A, Rahman S, Rahmat J, Rajkarnikar P, Ramanjulu R, Ramasubramanian A, Ramirez-Ortiz MA, Raobela L, Rashid R, Reddy MA, Reich E, Renner LA, Reynders D, Ribadu D, Riheia MM, Ritter-Sovinz P, Rojanaporn D, Romero L, Roy SR, Saab RH, Saakyan S, Sabhan AH, Sagoo MS, Said AMA, Saiju R, Salas B, San Román Pacheco S, Sánchez GL, Sayalith P, Scanlan TA, Schefler AC, Schoeman J, Sedaghat A, Seregard S, Seth R, Shah AS, Shakoor SA, Sharma MK, Sherief ST, Shetye NG, Shields CL, Siddiqui SN, Sidi Cheikh S, Silva S, Singh AD, Singh N, Singh U, Singha P, Sitorus RS, Skalet AH, Soebagjo HD, Sorochynska T, Ssali G, Stacey AW, Staffieri SE, Stahl ED, Stathopoulos C, Stirn Kranjc B, Stones DK, Strahlendorf C, Suarez MEC, Sultana S, Sun X, Sundy M, Superstein R, Supriyadi E, Surukrattanaskul S, Suzuki S, Svojgr K, Sylla F, Tamamyan G, Tan D, Tandili A, Tarrillo Leiva FF, Tashvighi M, Tateshi B, Tehuteru ES, Teixeira LF, Teh KH, Theophile T, Toledano H, Trang DL, Traoré F, Trichaiyaporn S, Tuncer S, Tyau-Tyau H, Umar AB, Unal E, Uner OE, Urbak SF, Ushakova TL, Usmanov RH, Valeina S, van Hoefen Wijsard M, Varadisai A, Vasquez L, Vaughan LO, Veleva-Krasteva NV, Verma N, Victor AA, Viksnins M, Villacís Chafla EG, Vishnevskia-Dai V, Vora T, Wachtel AE, Wackernagel W, Waddell K, Wade PD, Wali AH, Wang YZ, Weiss A, Wilson MW, Wime ADC, Wiwatwongwana A, Wiwatwongwana D, Wolley Dod C, Wongwai P, Xiang D, Xiao Y, Yam JC, Yang H, Yanga JM, Yaqub MA, Yarovaya VA, Yarovoy AA, Ye H, Yousef YA, Yuliawati P, Zapata López AM, Zein E, Zhang C, Zhang Y, Zhao J, Zheng X, Zhilyaeva K, Zia N, Ziko OAO, Zondervan M, Bowman R. Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA Oncol 2020; 6:685-695. [PMID: 32105305 PMCID: PMC7047856 DOI: 10.1001/jamaoncol.2019.6716] [Citation(s) in RCA: 144] [Impact Index Per Article: 36.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Importance Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. Objectives To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. Design, Setting, and Participants A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. Main Outcomes and Measures Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. Results The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were female. Most patients (n = 3685 [84.7%]) were from low- and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 [95% CI, 4.30-7.68]). Conclusions and Relevance This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs.
Collapse
Affiliation(s)
| | - Ido Didi Fabian
- International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
- The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel
| | - Elhassan Abdallah
- Ophthalmology Department of Rabat, Mohammed V University, Rabat, Morocco
| | | | | | | | | | - Adedayo Adio
- Department of Ophthalmology, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria
| | | | | | - Ada E Aghaji
- Department of Ophthalmology, College of Medicine, University of Nigeria, Enugu, Nigeria
| | - Alia Ahmad
- The Children's Hospital and the Institute of Child Health, Lahore, Pakistan
| | | | - Lamis Al Harby
- The Royal London Hospital, Barts Health NHS Trust, and Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
| | | | - Aygun Alakbarova
- Zarifa Aliyeva National Center of Ophthalmology, Baku, Azerbaijan
| | | | - Safaa A F Al-Badri
- Pediatric Oncology Unit, Children Welfare Teaching Hospital, College of Medicine, University of Baghdad, Baghdad, Iraq
| | | | | | - Amanda Alejos
- Unidad Nacional de Oncología Pediátrica, Guatemala City, Guatemala
| | | | | | | | - Christiane Al-Haddad
- Department of Ophthalmology, American University of Beirut Medical Center, Beirut, Lebanon
| | | | - Amany M Ali
- Pediatric Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
| | - Donjeta B Alia
- University Hospital Center Mother Theresa, Tirana, Albania
| | - Mazin F Al-Jadiry
- Pediatric Oncology Unit, Children Welfare Teaching Hospital, College of Medicine, University of Baghdad, Baghdad, Iraq
| | | | - Hind M Alkatan
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | | | | | | | | | | | | | | | | | - Nicholas J Astbury
- International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
| | - Hatice T Atalay
- Department of Ophthalmology, School of Medicine, Gazi University, Ankara, Turkey
| | | | - Rose Atsiaya
- Lighthouse For Christ Eye Centre, Mombasa, Kenya
| | - Taweevat Attaseth
- Department of Ophthalmology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Than H Aung
- Yangon Eye Hospital, University of Medicine 1, Yangon, Myanmar
| | | | - Baglan Baizakova
- Scientific Center of Pediatrics and Pediatric Surgery, Almaty, Kazakhstan
| | - Julia Balaguer
- Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | | | - Walentyna Balwierz
- Institute of Pediatrics, Jagiellonian University Medical College, Children's University Hospital of Krakow, Krakow, Poland
| | - Honorio Barranco
- Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Covadonga Bascaran
- International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
| | - Maja Beck Popovic
- Pediatric Hematology-Oncology Unit, Lausanne University Hospital, Lausanne, Switzerland
| | - Raquel Benavides
- Hospital Nacional de Niños Dr Carlos Sáenz Herrera, San Jose, Costa Rica
| | - Sarra Benmiloud
- Department of Pediatric Oncology, University Hassan II Fès, Fez, Morocco
| | | | - Rokia C Berete
- Ophthalmologic Department of the Teaching Hospital of Treichville, Abidjan, Côte d'Ivoire
| | - Jesse L Berry
- Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles
| | | | - Sunil Bhat
- Department of Pediatric Hematology and Oncology, Narayana Health City, Bangalore, India
| | | | - Eva M Biewald
- Department of Ophthalmology, Essen University Hospital, University Duisburg-Essen, Essen, Germany
| | - Nadia Bobrova
- The Filatov Institute of Eye Diseases and Tissue Therapy, Odessa, Ukraine
| | - Marianna Boehme
- Department of Ophthalmology, Essen University Hospital, University Duisburg-Essen, Essen, Germany
| | - H C Boldt
- Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City
| | | | - Norbert Bornfeld
- Department of Ophthalmology, Essen University Hospital, University Duisburg-Essen, Essen, Germany
| | - Gabrielle C Bouda
- Centre Hospitalier Universitaire Yalgado Ouédraogo de Ouagadougou, Ouagadougou, Burkina Faso
| | - Hédi Bouguila
- Institut Hédi Raïs d'Ophtalmologie, Faculté de Médecine, Université Tunis El Manar, Tunis, Tunisia
| | - Amaria Boumedane
- Etablissement Hospitalière Spécialise Emir Abdelkader CEA Service d'Oncologie Pédiatrique, Oran, Algeria
| | - Rachel C Brennan
- Solid Tumor Division, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | | | | | | | | | - Jayne E Camuglia
- Department of Ophthalmology, Queensland Children's Hospital, Brisbane, Queensland, Australia
| | - Miriam R Cano
- Salud Ocular, Ministerio de Salud Publica, Asuncion, Paraguay
| | | | - Nathalie Cassoux
- Institut Curie, Université de Paris Medicine Paris V Descartes, Paris, France
| | - Guilherme Castela
- Centro Hospital Universitário de Coimbra, University of Coimbra, Coimbra, Portugal
| | | | | | - Guillermo L Chantada
- Hospital Sant Joan de Déu, Barcelona, Spain
- Hospital Garrahan, Buenos Aires, Argentina
- NationalScientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| | - Shabana Chaudhry
- Paediatric Ophthalmology Department, Mayo Hospital and College of Allied Visual Sciences, King Edward Medical University, Lahore, Pakistan
| | - Sonal S Chaugule
- Department of Ophthalmic Plastic Surgery, Orbit and Ocular Oncology, PBMA's H. V. Desai Eye Hospital, Pune, Maharashtra, India
| | | | - Bhavna Chawla
- Ocular Oncology Service, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India
| | - Violeta S Chernodrinska
- Eye Clinic, Department of Ophthalmology, University Hospital Alexandrovska, Medical University, Sofia, Sofia, Bulgaria
| | | | | | - Krzysztof Cieslik
- Department of Ophthalmology, The Children's Memorial Health Institute, Warsaw, Poland
| | | | - Codruta Comsa
- Institute of Oncology, Prof. Dr Al. Trestioreanu, Bucharest, Romania
| | - Zelia M Correa
- Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, Maryland, and University of Cincinnati College of Medicine, Cincinnati, Ohio
| | | | | | | | | | - Xuehao Cui
- Department of Ophthalmology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | | | - Wantanee Dangboon
- Department of Ophthalmology, Songklanagarind Hospital, Prince of Songkla University, Songkla, Thailand
| | - Anirban Das
- Department of Pediatric Hematology-Oncology, Tata Medical Center, Kolkata, India
| | - Sima Das
- Ocular Oncology Services, Dr Shroff's Charity Eye Hospital, New Delhi, India
| | | | - Alan Davidson
- Red Cross War Memorial Children's Hospital and the University of Cape Town, Cape Town, South Africa
| | | | | | - Hakan Demirci
- Department of Ophthalmology, Kellogg Eye Center, University of Michigan, Ann Arbor
| | | | | | - Helen Dimaras
- The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Andrew J Dodgshun
- Department of Paediatrics, University of Otago, Christchurch, Children's Haematology and Oncology Center, Christchurch Hospital, Christchurch, New Zealand
| | - Craig Donaldson
- The Children's Hospital at Westmead, Sydney, New South Wales, Australia
| | | | - Monica D Dragomir
- Institute of Oncology, Prof. Dr Al. Trestioreanu, Bucharest, Romania
| | - Yi Du
- Department of Ophthalmology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | | | - Kemala S Edison
- Ophthalmology Department, Dr M. Djamil General Hospital, Faculty of Medicine, Andalas University, West Sumatra, Indonesia
| | - I Wayan Eka Sutyawan
- Department of Ophthalmology, Faculty of Medicine, Udayana University, Sanglah Eye Hospital, Bali, Indonesia
| | - Asmaa El Kettani
- Center Hospitalier et Universitaire Ibn Rochd, Casablanca, Morocco
| | - Amal M Elbahi
- Tripoli Eye Hospital, University of Tripoli, Tripoli, Libya
| | - James E Elder
- Department of Ophthalmology, Royal Children's Hospital, Parkville, Victoria, Australia
- Department of Paediatrics, Melbourne Medical School, University of Melbourne, Parkville, Victoria, Australia
| | - Dina Elgalaly
- Children's Cancer Hospital Egypt 57357, Cairo, Egypt
| | | | - Moawia M Ali Elhassan
- Department of Oncology, National Cancer Institute, University of Gezira, Wadi Madani, Sudan
| | - Mahmoud M Elzembely
- Pediatric Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
| | - Vera A Essuman
- Ophthalmology Unit, Department of Surgery, School of Medicine and Dentistry, University of Ghana, Accra, Ghana
| | | | | | | | - Mohammad Faranoush
- Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Rasool Akram Hospital, Tehran, Iran
| | - Oluyemi Fasina
- Department of Ophthalmology, University College Hospital, University of Ibadan, Ibadan, Nigeria
| | | | | | - Allen Foster
- International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
| | - Shahar Frenkel
- Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel
| | | | - Soad L Fuentes-Alabi
- Pediatric Oncology Department, Benjamin Bloom National Children's Hospital, San Salvador, El Salvador
| | | | - Moira Gandiwa
- Lions Sight First Eye Hospital, Queen Elizabeth Central Hospital, Blantyre, Malawi
| | | | | | | | - Jennifer A Geel
- Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
| | - Fariba Ghassemi
- Retina and Vitreous Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Ana V Girón
- Unidad Nacional de Oncología Pediátrica, Guatemala City, Guatemala
| | - Zelalem Gizachew
- Department of Ophthalmology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia
| | - Marco A Goenz
- Pediatric Oncology Department, Benjamin Bloom National Children's Hospital, San Salvador, El Salvador
| | - Aaron S Gold
- Murray Ocular Oncology and Retina, Miami, Florida
| | | | - Glen A Gole
- Department of Ophthalmology, Queensland Children's Hospital, Brisbane, Queensland, Australia
| | - Nir Gomel
- Department of Ophthalmology, Sourasky Medical Center Tel Aviv, School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Efren Gonzalez
- Department of Ophthalmology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
| | | | | | - Henry N Garcia Pacheco
- Pediatric Oncology Unit, Instituto Regional de Enfermedades Neoplásicas del Sur, Arequipa, Perú
| | - Jaime Graells
- Unidad de Oncologia Ocular Hospital Oncologico Luis Razzetti, Caracas, Venezuela
| | - Liz Green
- IAM NOOR Eye Care Programme, Afghanistan
| | - Pernille A Gregersen
- Department of Clinical Genetics and Center for Rare Disorders, Aarhus University Hospital, Aarhus, Denmark
| | | | - Koffi M Guedenon
- Département de Pédiatrie, CHU Sylvanus Olympio, Université de Lomé, Lomé, Togo
| | | | - Ahmet K Gündüz
- Department of Ophthalmology, Ankara University School of Medicine, Ankara, Turkey
| | - Himika Gupta
- Bai Jerbai Wadia Hospital for Children, Mumbai, India
| | - Sanjiv Gupta
- King George's Medical University, Lucknow, India
| | | | - Patrick Hamel
- Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montréal, Quebec, Canada
| | | | | | - Eric D Hansen
- John A. Moran Eye Center, University of Utah, Salt Lake City
| | - J William Harbour
- Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
| | | | - Murat Hasanreisoglu
- Department of Ophthalmology, School of Medicine, Gazi University, Ankara, Turkey
| | - Sadiq Hassan
- Aminu Kano Teaching Hospital, Bayero University, Kano, Nigeria
| | - Shadab Hassan
- Department of Pediatric Ophthalmology and Strabismus, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan
| | | | - Jose Hernandez
- Hospital Nacional Guillermo Almenara Irigoyen, Lima, Perú
| | | | - Laila Hessissen
- Pediatric Hematology and Oncology Center, Mohammed V University, Rabat, Morocco
| | - Diriba F Hordofa
- Department of Pediatrics and Child Health, Jimma University Medical Center, Jimma, Ethiopia
| | - Laura C Huang
- Byers Eye Institute, Stanford University, Stanford, California
| | | | - Marlies Hummlen
- Department of Ophthalmology, Oslo University Hospital, Oslo, Norway
| | | | | | - Russo Ida
- Bambino Gesù IRCCS Children's Hospital, Rome, Italy
| | - Vesna R Ilic
- Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
| | | | | | - Helen Jenkinson
- Eye Department, Birmingham Children's Hospital, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom
| | - Xunda Ji
- Department of Ophthalmology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Dong Hyun Jo
- Fight Against Angiogenesis-Related Blindness Laboratory, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea
| | | | - William J Johnson
- Storm Eye Institute, Medical University of South Carolina, Charleston
| | - Michael M Jones
- The Children's Hospital at Westmead, Sydney, New South Wales, Australia
| | | | - Rolande L Kabore
- Centre Hospitalier Universitaire Yalgado Ouédraogo de Ouagadougou, Ouagadougou, Burkina Faso
| | - Swathi Kaliki
- Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, India
| | - Abubakar Kalinaki
- Department of Ophthalmology, Makerere University College of Health Sciences Kamplala, Uganda
| | - Mehmet Kantar
- Division of Pediatric Oncology, School of Medicine, Ege University, Izmir, Turkey
| | | | - Tamar Kardava
- Ophthalmology Department, Central Children's Hospital of Georgia, Tbilisi, Georgia
| | - Rejin Kebudi
- Division of Pediatric Hematology-Oncology, Department of Pediatrics, Cerrahpaşa Faculty of Medicine and Oncology Institute, Istanbul University, Istanbul, Turkey
| | - Tomas Kepak
- St. Anne's University Hospital Brno, Masaryk University, and International Clinical Research Center/St Anna University Hospital, Brno, Czech Republic
| | | | | | - Hussain A Khaqan
- Department of Ophthalmology, Postgraduate Medical Institute, Ameer-Ud-Din Medical College, Lahore General Hospital, Lahore, Pakistan
| | - Phara Khauv
- Angkor Hospital for Children, Krong Siem Reap, Cambodia
| | - Wajiha J Kheir
- Duke Eye Center, Duke University Hospital, Durham, North Carolina
| | | | - Alireza Khodabande
- Retina and Vitreous Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Zaza Khotenashvili
- Ophthalmology Department, Central Children's Hospital of Georgia, Tbilisi, Georgia
| | - Jonathan W Kim
- Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles
| | - Jeong Hun Kim
- Department of Ophthalmology, Seoul National University Hospital, Seoul, Republic of Korea
| | - Hayyam Kiratli
- Ocular Oncology Service, Department of Ophthalmology, Hacettepe University School of Medicine, Ankara, Turkey
| | - Tero T Kivelä
- Ocular Oncology Service, Department of Ophthalmology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Artur Klett
- East Tallinn Central Hospital, Tallinn, Estonia
| | | | - Dalia Krivaitiene
- Children's Ophthalmology Department, Children's Hospital of Vilnius, University Hospital Santaros Clinic, Vilnius, Lithuania
| | - Mariana Kruger
- Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa
| | - Kittisak Kulvichit
- Vitreo-Retina Research Unit, Department of Ophthalmology, Chulalongkorn University, Bangkok, Thailand
| | | | - Alice Kyara
- Muhimbili National Hospital, Dar es Salaam, Tanzania
| | - Eva S Lachmann
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Carol P S Lam
- Hong Kong Eye Hospital, Chinese University of Hong Kong, Hong Kong SAR, China
| | - Geoffrey C Lam
- Perth Children's Hospital, University of Western Australia, Perth, Western Australia, Australia
| | - Scott A Larson
- Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City
| | - Slobodanka Latinovic
- Clinical Center of Vojvodina, University Eye Clinic, Eye Research Foundation Vidar-Latinović, Novi Sad, Serbia
| | - Kelly D Laurenti
- Division of Ophthalmology, Feinberg School of Medicine, Northwestern University, and Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
| | - Bao Han A Le
- John A. Burns School of Medicine, University of Hawaii, Honolulu, and University of Southern California Roski Eye Institute, Los Angeles
| | - Karin Lecuona
- Division of Ophthalmology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | | | - Cairui Li
- Affiliated Hospital of Dali University, Dali City, China
| | - Ben Limbu
- Tilganga Institute of Ophthalmology, Kathmandu, Nepal
| | | | - Juan P López
- Ophthalmology Department, Faculty of Medicine, Universidad de Chile, Santiago, Chile
| | - Robert M Lukamba
- University Clinics of Lubumbashi, University of Lubumbashi, Lubumbashi, Democratic Rrepublic of Congo
| | | | - Sandra Luna-Fineman
- Pediatric Hematology/Oncology/Stem Cell Transplantation, Center for Global Health, Children's Hospital Colorado, University of Colorado, Aurora
| | - Delfitri Lutfi
- Department of Ophthalmology, Dr Soetomo General Hospital, Airlangga University, Surabaya, Indonesia
| | | | - George N Magrath
- Storm Eye Institute, Medical University of South Carolina, Charleston
| | - Amita Mahajan
- Pediatric Hematology-Oncology Unit, Apollo Center for Advanced Pediatrics, Indraprastha Apollo Hospital, New Delhi, India
| | | | - Erika Maka
- Semmelweis University, Budapest, Hungary
| | - Mayuri Makan
- Sekuru Kaguvi Eye Unit, Parirenyatwa Group of Hospitals, Harare, Zimbabwe
| | | | - Chatonda Manda
- Lions Sight First Eye Hospital, Queen Elizabeth Central Hospital, Blantyre, Malawi
| | - Nieves Martín Begue
- Department of Pediatric Ophthalmology, Hospital Vall d'Hebron, Barcelona, Spain
| | | | | | | | - Miguel Materin
- Duke Eye Center, Duke University Hospital, Durham, North Carolina
| | | | - Marchelo Matua
- Ruharo Eye Centre, Ruharo Mission Hospital, Mbarara, Uganda
| | - Ismail Mayet
- University of the Witwatersrand, Johannesburg, South Africa
| | | | - John D McKenzie
- Department of Ophthalmology, Royal Children's Hospital, Parkville, Victoria, Australia
- Department of Ocular Oncology, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia
| | - Aurora Medina-Sanson
- Department of Oncology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
| | - Azim Mehrvar
- MAHAK Hematology Oncology Research Center, Mahak Hospital, Tehran, Iran
| | | | | | | | - Marilyn B Mets
- Division of Ophthalmology, Feinberg School of Medicine, Northwestern University, and Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
| | - Edoardo Midena
- Department of Ophthalmology, University of Padova, Padova, Italy
| | | | | | - Ahmed A Mohamedani
- Department of Pathology, Faculty of Medicine, University of Gezira, Wad Medani, Sudan
| | | | - Annette C Moll
- Department of Ophthalmology, Amsterdam UMC, Amsterdam, the Netherlands
| | | | - Rosa A Morales
- Hospital Infantil Manuel de Jesús Rivera, Managua, Nicaragua
| | - Claude Moreira
- Service d'Oncologie Pédiatrique de l'Hôpital Aristide le Dantec, Dakar, Senegal
| | | | | | - Gerald Msukwa
- Lions Sight First Eye Hospital, Queen Elizabeth Central Hospital, Blantyre, Malawi
| | | | | | - Francis L Munier
- Jules-Gonin Eye Hospital, Fondation Asile de Aveugles, University of Lausanne, Lausanne, Switzerland
| | - Gabriela Murgoi
- Institute of Oncology, Prof. Dr Al. Trestioreanu, Bucharest, Romania
| | | | - Kareem O Musa
- Department of Ophthalmology, Lagos University Teaching Hospital, College of Medicine of the University of Lagos, Lagos, Nigeria
| | - Asma Mushtaq
- The Children's Hospital and the Institute of Child Health, Lahore, Pakistan
| | - Hamzah Mustak
- Division of Ophthalmology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | | | - Gita Naidu
- University of the Witwatersrand, Johannesburg, South Africa
| | - Akshay Gopinathan Nair
- Aditya Jyot Eye Hospital, Mumbai, India
- Lokmanya Tilak Municipal General Hospital and Medical College, Mumbai, India
| | - Larisa Naumenko
- N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus
| | | | - Yetty M Nency
- Child Health Department, Faculty of Medicine, Diponegoro University, Semarang, Indonesia
| | - Vladimir Neroev
- Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia
| | - Hang Ngo
- Ho Chi Minh Eye Hospital, Ho Chi Minh, Vietnam
| | - Rosa M Nieves
- Hospital Infantil Dr Robert Reid Cabral, Santo Domingo, Dominican Republic
| | - Marina Nikitovic
- Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
| | - Elizabeth D Nkanga
- Department of Ophthalmology, Calabar Children's Eye Center, University of Calabar Teaching Hospital, Calabar Nigeria
| | - Henry Nkumbe
- Magrabi ICO Cameroon Eye Institute, Yaounde, Cameroon
| | - Murtuza Nuruddin
- Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh
| | | | | | - Ngozi C Oguego
- Department of Ophthalmology, College of Medicine, University of Nigeria, Enugu, Nigeria
| | - Andrzej Olechowski
- Department of Ophthalmology, The Children's Memorial Health Institute, Warsaw, Poland
| | - Scott C N Oliver
- Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora
| | | | - Diego Ossandon
- Clínica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile
| | | | | | - Sally L Painter
- Eye Department, Birmingham Children's Hospital, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom
| | | | - Luisa Paiva
- National Ophthalmological Institute of Angola, Luanda, Angola
| | - Bikramjit P Pal
- H M Diwan Eye Foundation, and Tata Medical Center, Kolkata, India
| | | | - Ruzanna Papyan
- Department of Oncology, Yerevan State Medical University, and Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after R. H. Yeolyan, Yerevan, Armenia
| | | | - Manoj Parulekar
- Eye Department, Birmingham Children's Hospital, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom
| | | | | | - Katarzyna Pawinska-Wasikowska
- Institute of Pediatrics, Jagiellonian University Medical College, Children's University Hospital of Krakow, Krakow, Poland
| | - Jacob Pe'er
- Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel
| | | | - Sanja Peric
- University Hospital Center Zagreb, Zagreb, Croatia
| | - Chau T M Pham
- Vietnam National Institute of Ophthalmology, Ha Noi, Vietnam
| | - Remezo Philbert
- Centre Hospitalier Universitaire de Kamenge, Bujumbura, Burundi
| | | | - Pavel Pochop
- Department of Ophthalmology for Children and Adults, Second Faculty of Medicine, Charles University, and Motol University Hospital, Prague, Czech Republic
| | | | - Vladimir G Polyakov
- Head and Neck Tumors Department, SRI of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia
- Russian Medical Academy of Postgraduate Education, Moscow, Russia
| | - Manca T Pompe
- University Eye Hospital Ljubljana, University Medical Center Ljubljana, Ljubljana, Slovenia
| | | | - Daphna Prat
- The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel
| | | | - Ignatius Purwanto
- Sardjito Hospital, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
| | | | - Seema Qayyum
- The Children's Hospital and the Institute of Child Health, Lahore, Pakistan
| | - Jiang Qian
- Department of Ophthalmology, Eye and Ear, Nose, and Throat Hospital of Fudan University, Shanghai, China
| | - Ardizal Rahman
- Ophthalmology Department, Dr M. Djamil General Hospital, Faculty of Medicine, Andalas University, West Sumatra, Indonesia
| | | | | | | | | | | | - Marco A Ramirez-Ortiz
- Department of Ophthalmology, Hospital Infantil de Mexico Federico Gómez, Mexico City, Mexico
| | - Léa Raobela
- Centre Hospitalier Universitaire Joseph Ravoahangy Andrianavalona, Antananarivo, Madagascar
| | - Riffat Rashid
- Department of Oculoplasty and Ocular Oncology, Ispahani Islamia Eye Institute and Hospital, Dhaka, Bangladesh
| | - M Ashwin Reddy
- The Royal London Hospital, Barts Health NHS Trust, and Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
| | - Ehud Reich
- Department of Ophthalmology, Davidoff Center for Oncology, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Israel
| | - Lorna A Renner
- School of Medicine and Dentistry, Korle-Bu Teaching Hospital, University of Ghana, Accra, Ghana
| | | | | | | | - Petra Ritter-Sovinz
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - Duangnate Rojanaporn
- Department of Ophthalmology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Livia Romero
- Unidad de Oncologia Ocular Hospital Oncologico Luis Razzetti, Caracas, Venezuela
| | - Soma R Roy
- Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh
| | - Raya H Saab
- Children's Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon
| | - Svetlana Saakyan
- Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia
| | - Ahmed H Sabhan
- Pediatric Oncology Unit, Children Welfare Teaching Hospital, College of Medicine, University of Baghdad, Baghdad, Iraq
| | - Mandeep S Sagoo
- NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, and UCL Institute of Ophthalmology and London Retinoblastoma Service, Royal London Hospital, London, United Kingdom
| | - Azza M A Said
- Department of Ophthalmology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Rohit Saiju
- Tilganga Institute of Ophthalmology, Kathmandu, Nepal
| | - Beatriz Salas
- Hospital Dr Manuel Ascencio Villarroel, Cochabamba, Bolivia
| | | | | | | | | | | | | | - Ahad Sedaghat
- Department of Ophthalmology, Rasool Akram Hospital, Tehran, Iran
| | | | - Rachna Seth
- Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
| | - Ankoor S Shah
- Department of Ophthalmology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
| | | | | | - Sadik T Sherief
- Department of Ophthalmology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia
| | | | - Carol L Shields
- Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Sorath Noorani Siddiqui
- Department of Pediatric Ophthalmology and Strabismus, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan
| | - Sidi Sidi Cheikh
- Ophthalmology Department, Nouakchott Medical University, Nouakchott, Mauritania
| | - Sónia Silva
- Centro Hospital Universitário de Coimbra, University of Coimbra, Coimbra, Portugal
| | - Arun D Singh
- Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
| | | | - Usha Singh
- Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Penny Singha
- Department of Ophthalmology, Songklanagarind Hospital, Prince of Songkla University, Songkla, Thailand
| | - Rita S Sitorus
- Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, and Dr Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
| | - Alison H Skalet
- Casey Eye Institute, Oregon Health & Science University, Portland
| | - Hendrian D Soebagjo
- Department of Ophthalmology, Dr Soetomo General Hospital, Airlangga University, Surabaya, Indonesia
| | | | - Grace Ssali
- Mulago National Referral Hospital, Kampala, Uganda
| | - Andrew W Stacey
- Department of Ophthalmology, University of Washington, Seattle
| | - Sandra E Staffieri
- Department of Ophthalmology, Royal Children's Hospital, Parkville, Victoria, Australia
- Centre for Eye Research Australia, University of Melbourne, East Melbourne, Victoria, Australia
| | - Erin D Stahl
- Children's Mercy Hospital, Kansas City, Missouri
| | - Christina Stathopoulos
- Jules-Gonin Eye Hospital, Fondation Asile de Aveugles, University of Lausanne, Lausanne, Switzerland
| | - Branka Stirn Kranjc
- University Eye Hospital Ljubljana, University Medical Center Ljubljana, Ljubljana, Slovenia
| | - David K Stones
- Department of Paediatrics and Child Health, University of the Free State, Bloemfontein, South Africa
| | | | | | - Sadia Sultana
- Department of Oculoplasty and Ocular Oncology, Ispahani Islamia Eye Institute and Hospital, Dhaka, Bangladesh
| | - Xiantao Sun
- Henan Children's Hospital, Affiliated Children's Hospital of Zhengzhou University, Zhengzhou, China
| | - Meryl Sundy
- Casey Eye Institute, Oregon Health & Science University, Portland
| | - Rosanne Superstein
- Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montréal, Quebec, Canada
| | - Eddy Supriyadi
- Sardjito Hospital, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
| | | | - Shigenobu Suzuki
- Department of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Karel Svojgr
- Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic
| | | | - Gevorg Tamamyan
- Department of Oncology, Yerevan State Medical University, and Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after R. H. Yeolyan, Yerevan, Armenia
| | - Deborah Tan
- Singapore National Eye Center, Singapore, Singapore
| | - Alketa Tandili
- University Hospital Center Mother Theresa, Tirana, Albania
| | | | - Maryam Tashvighi
- MAHAK Hematology Oncology Research Center, Mahak Hospital, Tehran, Iran
| | | | - Edi S Tehuteru
- National Cancer Center, Dharmais Cancer Hospital, Jakarta, Indonesia
| | - Luiz F Teixeira
- Pediatric Oncology Institute, Federal University of São Paulo, São Paulo, Brazil
- Ophthalmology Department, Federal University of São Paulo, São Paulo, Brazil
| | - Kok Hoi Teh
- Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
| | | | - Helen Toledano
- Department of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Doan L Trang
- Vietnam National Institute of Ophthalmology, Ha Noi, Vietnam
| | - Fousseyni Traoré
- Pediatric Oncology Service, Gabriel Toure Hospital, Bamako, Mali
| | | | - Samuray Tuncer
- Department of Ophthalmology, Faculty of Medicine, Ocular Oncology Service, Istanbul University, Istanbul, Turkey
| | | | - Ali B Umar
- Aminu Kano Teaching Hospital, Bayero University, Kano, Nigeria
| | - Emel Unal
- Division of Pediatric Hematology-Oncology, Department of Pediatrics, Ankara University, Ankara, Turkey
| | | | - Steen F Urbak
- Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark
| | - Tatiana L Ushakova
- Head and Neck Tumors Department, SRI of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia
- Russian Medical Academy of Postgraduate Education, Moscow, Russia
| | | | | | | | - Adisai Varadisai
- Vitreo-Retina Research Unit, Department of Ophthalmology, Chulalongkorn University, Bangkok, Thailand
| | | | | | - Nevyana V Veleva-Krasteva
- Eye Clinic, Department of Ophthalmology, University Hospital Alexandrovska, Medical University, Sofia, Sofia, Bulgaria
| | | | - Andi A Victor
- Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, and Dr Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
| | | | | | - Vicktoria Vishnevskia-Dai
- The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel
| | | | | | | | - Keith Waddell
- Ruharo Eye Centre, Ruharo Mission Hospital, Mbarara, Uganda
| | | | | | - Yi-Zhuo Wang
- Department of Paediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China
| | - Avery Weiss
- Department of Ophthalmology, University of Washington, Seattle
| | - Matthew W Wilson
- Department of Surgery, St Jude Children's Research Hospital, Memphis, Tennessee
| | - Amelia D C Wime
- National Ophthalmological Institute of Angola, Luanda, Angola
| | | | | | | | - Phanthipha Wongwai
- Department of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | - Daoman Xiang
- Department of Pediatric Ophthalmology, Guangzhou Children's Hospital and Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China
| | | | - Jason C Yam
- Hong Kong Eye Hospital, Chinese University of Hong Kong, Hong Kong SAR, China
| | - Huasheng Yang
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
| | - Jenny M Yanga
- Service d'Ophtalmologie, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Kinshasa, Democratic Republic of Congo
| | | | - Vera A Yarovaya
- S.Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia
| | - Andrey A Yarovoy
- S.Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia
| | - Huijing Ye
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
| | | | - Putu Yuliawati
- Department of Ophthalmology, Faculty of Medicine, Udayana University, Sanglah Eye Hospital, Bali, Indonesia
| | | | - Ekhtelbenina Zein
- Assistante Hospitalo Universitaire, Faculte de Medecine de Nouakchott Medecin Oncopediatre, Center National d'Oncologie, Nouakchott, Mauritania
| | - Chengyue Zhang
- Department of Ophthalmology, Beijing Children's Hospital, Capital Medical University, Beijing, China
| | - Yi Zhang
- Department of Paediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China
| | - Junyang Zhao
- Department of Ophthalmology, Beijing Children's Hospital, Capital Medical University, Beijing, China
| | - Xiaoyu Zheng
- Department of Ophthalmology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | | | - Nida Zia
- The Indus Hospital, Karachi, Pakistan
| | - Othman A O Ziko
- Department of Ophthalmology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Marcia Zondervan
- International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
| | - Richard Bowman
- International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
- Ophthalmology Department, Great Ormond Street Hospital, London, United Kingdom
| |
Collapse
|
19
|
Uner OE, Rao P, Hubbard GB. Reactivation of Retinopathy of Prematurity in Adults and Adolescents. Ophthalmol Retina 2020; 4:720-727. [PMID: 32224099 DOI: 10.1016/j.oret.2020.02.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2019] [Revised: 01/30/2020] [Accepted: 02/03/2020] [Indexed: 11/26/2022]
Abstract
PURPOSE To review the clinical features, treatment outcomes, and prevalence within our clinic population of adolescents and adults with previously regressed retinopathy of prematurity (ROP) who demonstrate late-onset exudation and vasoproliferative changes. DESIGN Retrospective review of consecutive patients at a single center. PARTICIPANTS Five patients (5 eyes) with a history of ROP who showed new exudates or worsening fibrovascular proliferation diagnosed after 10 years of age. METHODS Patients were identified by a computerized search of the Emory Eye Center billing records. Data extracted from charts included baseline ROP information, visual acuity and other examination findings, imaging, and treatments. MAIN OUTCOME MEASURES Status of exudation and vasoproliferation. RESULTS Among 138 patients older than 10 years with ROP seen at our tertiary referral center from 2000 through 2018, 5 (3.6%) demonstrated late-onset exudation or vasoproliferation. Three patients were female and 3 underwent ROP treatment as neonates. Mean age at onset of late reactivation was 25.6 years (range, 13-43 years). Previous treatments for neonatal ROP included peripheral laser ablation (n = 3), scleral buckle (n = 2), pars plicata vitrectomy (n = 2), and no treatment (n = 2). Management strategies for late reactivation included observation (n = 1), intravitreal anti-vascular endothelial growth factor agents (n = 4), vitrectomy (n = 2), and cryotherapy (n = 1). With mean follow-up of 4.8 years (range, 1-7 years), outcomes were resolution of exudation or proliferation with return to baseline vision (n = 2), stable mild exudation (n = 1), and progressive vasoproliferation with traction leading to phthisis (n = 2). CONCLUSIONS Late-onset exudation and fibrovascular proliferation in adolescents and adults with ROP can occur rarely with previously regressed ROP. Two of 5 patients were refractory to all treatments and demonstrated phthisis bulbi. One patient showed reactivation in the form of a reactive retinal astrocytic tumor. Our findings highlight the importance continued monitoring with regular fundus examination in adolescents and adults with regressed ROP.
Collapse
Affiliation(s)
- Ogul E Uner
- Emory University School of Medicine, Atlanta, Georgia
| | - Prethy Rao
- Emory University School of Medicine, Atlanta, Georgia; The Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia
| | - G Baker Hubbard
- Emory University School of Medicine, Atlanta, Georgia; The Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia.
| |
Collapse
|
20
|
Gupta P, Uner OE, Nayak S, Grant GR, Kalb RG. SAP97 regulates behavior and expression of schizophrenia risk enriched gene sets in mouse hippocampus. PLoS One 2018; 13:e0200477. [PMID: 29995933 PMCID: PMC6040763 DOI: 10.1371/journal.pone.0200477] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Accepted: 06/27/2018] [Indexed: 01/10/2023] Open
Abstract
Synapse associated protein of 97KDa (SAP97) belongs to a family of scaffolding proteins, the membrane-associated guanylate kinases (MAGUKs), that are highly enriched in the postsynaptic density of synapses and play an important role in organizing protein complexes necessary for synaptic development and plasticity. The Dlg-MAGUK family of proteins are structurally very similar, and an effort has been made to parse apart the unique function of each Dlg-MAGUK protein by characterization of knockout mice. Knockout mice have been generated and characterized for PSD-95, PSD-93, and SAP102, however SAP97 knockout mice have been impossible to study because the SAP97 null mice die soon after birth due to a craniofacial defect. We studied the transcriptomic and behavioral consequences of a brain-specific conditional knockout of SAP97 (SAP97-cKO). RNA sequencing from hippocampi from control and SAP97-cKO male animals identified 67 SAP97 regulated transcripts. As large-scale genetic studies have implicated MAGUKs in neuropsychiatric disorders such as intellectual disability, autism spectrum disorders, and schizophrenia (SCZ), we analyzed our differentially expressed gene (DEG) set for enrichment of disease risk-associated genes, and found our DEG set to be specifically enriched for SCZ-related genes. Subjecting SAP97-cKO mice to a battery of behavioral tests revealed a subtle male-specific cognitive deficit and female-specific motor deficit, while other behaviors were largely unaffected. These data suggest that loss of SAP97 may have a modest contribution to organismal behavior. The SAP97-cKO mouse serves as a stepping stone for understanding the unique role of SAP97 in biology.
Collapse
Affiliation(s)
- Preetika Gupta
- Neuroscience Graduate Group, Department of Neuroscience, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Ogul E. Uner
- School of Arts and Sciences, Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Soumyashant Nayak
- Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Gregory R. Grant
- Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
- Department of Genetics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Robert G. Kalb
- Feinberg School of Medicine, Department of Neurology, Northwestern University, Chicago, Illinois, United States of America
| |
Collapse
|
21
|
Affiliation(s)
- Ogul E Uner
- Emory University School of Medicine, Atlanta, Georgia
| | | | | |
Collapse
|